metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	2	0.58 [0.46; 0.74], 2 RCTs, I2=0% conclusive high degree of certainty	0.41 [0.32; 0.53], 2 RCTs, I2=0% conclusive high degree of certainty	-
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	0.65 [0.53; 0.80], 1 RCT, I2=0% unassessable degree of certainty	0.74 [0.60; 0.92], 1 RCT, I2=0% unassessable degree of certainty	-
	relatlimab plus nivolumab vs. nivolumab alone	1	-	0.75 [0.62; 0.91], 1 RCT, I2=0% unassessable degree of certainty	-
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	1.44 [0.46; 4.49], 1 RCT, I2=0% inconclusive result	0.38 [0.15; 0.98], 1 RCT, I2=0% unassessable degree of certainty	-
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	-	0.40 [0.23; 0.69], 1 RCT, I2=0% conclusive unassessable degree of certainty	-